Greg Kunst Email and Phone Number
Greg Kunst work email
- Valid
Greg Kunst personal email
I am a Chief Executive Officer and Board Director accelerating global business growth and market expansion for biotech, pharmaceutical, and medical technology industries. My experience includes strategically planning, developing, and launching new products that have successfully expanded access to new and existing markets.In addition to my work in organizational and product development, I am accustomed to serving as a Board Director and Strategic Advisor to multiple organizations. As Board Director at Pr3vent, I’m transforming the industry landscape through my expertise in product management and strategic planning to deliver innovative healthcare solutions.EXPERTISE:➥ Strength in leading all functional areas of an organization while building partnerships, pushing expansion opportunities, and maintaining a forward-focused growth pattern.➥ Extensive experience steering new drug development and commercialization initiatives through pre-clinical, clinical, regulatory, and manufacturing strategies.➥ Proven history raising $300M+ in capital through equity and debt based on a deep relationship with big pharma strategics, M&A practices, and partnering opportunities.➥ A capacity to connect and lead roundtable discussions with C-level and Board leaders and develop new medical treatments, devises, and drugs for global market distribution.➥ Talent for developing numerous new therapeutic areas that shaped how medicine is practices including negative-pressure would therapy, micro-invasive glaucoma surgery, retina pharmaceuticals, and cell therapies.AWARDS:★ 2024 Ernst & Young Entrepreneur of the Year★ 2023 Puget Sound Business Journal Healthcare Leader of the Year★ 2022 Galien Foundation Prix Galien Award☛ Key Skills ☚ ✦ Strategy, Execution, & Leadership✦ Global Business Development✦ Continuous Improvement✦ Organizational Development✦ Product & Program Management✦ C-Level Thought Leadership✦ Fundraising & Investor Strategy✦ Policy & Process Development✦ Board Leadership & Public Speaking✦ Cross-Functional Collaboration✦ Team Leadership & Coaching✦ Medical & Government Affairs✦ Risk & Compliance Control✦ Stakeholder Engagement✦ Marketing & Brand Strategy✦ Change Management
Valitor
View- Website:
- valitorbio.com
- Employees:
- 20
-
Chief Executive Officer And Board MemberValitorUnited States
-
Founder, Chief Executive Officer, And Board DirectorAurion Biotech Apr 2021 - PresentSeattle, Washington, United StatesFounded new venture-backed startup from scratch to develop clinical-state cell therapy assets for eye diseases. Grew company from 1 to 90 employees and secured $132M+ in series-C venture backing from top-tier investors including Deerfield, KKR, Petrichor, and Alcon and +$200M in total venture financing. Oversaw development pipeline from pre-clinical development and technology transfer to drive development for new cell therapy. Received $50M in venture debt from the Bank of California.➥ Successfully separated startup from CorneaGen including shared service operations, physical facilities, policies, and procedures that led to strong, standalone operations and backing.➥ Cultivated relationships with key investors including Deerfield, Alcon, KKR, Petrichor, Visionary Ventures, and Flying L Ventures to raise $132M in series-C backing.➥ Steered lead cell therapy asset in preparation for 1/2 IND U.S. study and NDA submission in Japan.➥ Instrumental in gaining approval for first allogenic cell therapy in Japan and BTD / RMAT status approval in the U.S.➥ Prepared startup for future IPO activities by directing all business development and continuous improvement efforts in rapidly evolving industry. -
Board DirectorPr3Vent Inc Apr 2023 - PresentPalo Alto, California, United StatesCurrently serving as an independent Board Member for series A, venture-backed startup as well as a member of compensation and audit committees. -
Strategic AdvisorOculogica Jun 2019 - PresentNew York, New York, United States -
Vice President Global Marketing And Market AccessGlaukos Corporation Oct 2018 - Mar 2021San Clemente, Ca, United StatesBuilt and led commercial franchise team in strategizing and launching long-term product pipeline for $350M ophthalmic medical technology and pharmaceutical company. Led team of 40+ employees to propel key business initiatives in global marketing, business development, and medical affairs to strengthen company posture and visibility. Unlocked new market access by implementing strategic messaging and marketing strategies to fortify product positioning.➥ Promoted global expansion of pharmaceutical, medical device, and diagnostics offerings through rigorous pipeline development and product launches.➥ Led $500M M&A initiative integrating Avedro and Dose Medical with existing business.➥ Penetrated major markets on a global scale with the first minimally-invasive glaucoma device, iStent.➥ Accelerated company expansion by introducing more product offerings to single-product portfolio and 2 new business units. -
Senior Director, Global Market Access And Business DevelopmentGlaukos Corporation Apr 2015 - Oct 2018San Clemente, CaliforniaManaged key growth initiatives in global market reimbursement, international commercialization planning, and health technology assessments with global impact. Authored and executed targeted development and commercial plans based on global market trends including micro-invasive glaucoma surgery implants and drug delivery systems. Extended category 3 CPT code twice in 6 years.➥ Built, mentored, and led high-performance global team of 20 senior-level staff to drive global market access across Europe, the Middle East, Japan, Latin America, Canada, Australia, and Asia.➥ Orchestrated highly successful ophthalmic surgical implant launches with rapid reimbursement, physician, and facility reimbursement.
-
Global Marketing Director - Retina PharmaceuticalsAlcon Jul 2013 - Mar 2015Fort Worth, TxReinforced global launch, commercial, medical affairs, capabilities development, and market access infrastructure for first biologic / specialty pharmaceutical treatment for $12B ophthalmic pharmaceutical, medical device, and product global leader. Directed global marketing teams in executive rigorous commercial and market preparedness strategies for late-stage pipeline products in age-related macular degeneration.➥ Advanced product commercialization and development for Jetrea worldwide by building co-promotional partnerships with Novartis Opthalmics and Thrombogenics.➥ Adjusted product messaging on Jetrea following backlash in U.S. and German markets that improved launch results.➥ Oversaw largest business case and diligence on 3 large external opportunities in retina.➥ Instigated long-term retina pharma internal pipeline and business development strategy for largest category in eye care.➥ Consolidated Novartis Opthalmics and Alcon retina pharma salesforce and MSL infrastructures to promote continuity and growth. Defined salesforce and MSL operating model ensuring sustainable retina pharma business growth. -
Global Marketing Director - Surgical GlaucomaAlcon Mar 2010 - Jul 2013Fort Worth, TxGuided all development in global marketing, promotional, campaign, portfolio, product, M&A, and phase IV clinical trial strategies for new business unit. Launched new unit into 85+ global affiliates within 9 months including global infrastructure to ensure longevity and growth.➥ Seamlessly led integration of new business unit with global commercial infrastructure, devising entire glaucoma surgery portfolio strategy, internal development, and future acquisition opportunities.➥ Reversed poor performance of recently acquired glaucoma surgery business from $7M product line to $30M profit and 1-year run rate in 18 months following acquisition.
-
Director, Health Economics, Reimbursement, & Market Access - Asia Pacific And Latin America RegionsAcelity Aug 2009 - Mar 2010San Antonio, TexasPlayed an integral role commercializing flagship VAC therapy product line in Japan for $2.1B global leader in advanced wound care, regenerative medicine, and therapeutic surface products. Sat at the roundtable of the Asia Pacific (APAC) and Latin America executive teams tasked with driving market entry in new and competitive markets.➥ Negotiated with Ministries of Health and private insurance companies in APAC and Latin American regions to streamline coding, coverage, and payment procedures.➥ Developed new technical and medical material fees for VAC therapy with Japanese National Insurance System.➥ Established new societies for key opinion leaders and medical experts in new markets supporting successful payor coverage and product launch. -
Director, Global Reimbursement And Market AccessAcelity Feb 2008 - Aug 2009San Antonio, TexasBuilt first global reimbursement team to handle product reimbursement efforts for new and existing products including OUS government payors, U.S. private payors, Medicare, and state Medicaid. Lobbied congressional staff and federal agencies to change existing HCPCS coding for negative pressure wound therapy products.➥ Created clinical trials and publications that led to strong product market adoption and reimbursement coverage.➥ Curated congressional and legislative strategy and communications plan to exempt negative pressure wound therapy from round #1 of CMS bidding program.
-
Global Health Economics ManagerAcelity May 2006 - Feb 2008San Antonio, TexasBuilt new health economics and outcomes function for Europe, Canada, and the U.S. while developing global value dossiers for new and existing products. Designed studies to demonstrate positive clinical and cost impact of VAC therapy system that led to widespread buy in. Developed budget impact product models highlighting economic value to customers, payors, and providers.➥ Obtained initial German home care reimbursement by designing key clinical trial and patient registry program.➥ Fostered partnerships with global acute care facilities, integrated delivery networks, group purchasing organizations, managed care organizations, government payors, medical opinion leaders pivotal to product success.
-
Project ManagerCoopervision Jan 2003 - Oct 2004South San Francisco, California
Greg Kunst Education Details
-
Economics -
General Management And Strategy -
Strategy And Communications -
NovartisM2 Leadership Program - The Role Of The Leader -
Master Of Business Administration - Mba
Frequently Asked Questions about Greg Kunst
What company does Greg Kunst work for?
Greg Kunst works for Valitor
What is Greg Kunst's role at the current company?
Greg Kunst's current role is Chief Executive Officer and Board Member.
What is Greg Kunst's email address?
Greg Kunst's email address is gk****@****bio.com
What schools did Greg Kunst attend?
Greg Kunst attended Brigham Young University, Vanderbilt University - Owen Graduate School Of Management, The Tuck School Of Business At Dartmouth, Novartis, Vanderbilt University.
Who are Greg Kunst's colleagues?
Greg Kunst's colleagues are Livia Wilz Brier.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial